Statins in acute coronary syndromes: Start them in the hospital

Cleveland Clinic Journal of Medicine

Volumn 69, Issue 1, 2002, Pages 25-37

  Acevedo, Monica ^a   Sprecher, Dennis L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; COLLAGEN; FLUINDOSTATIN; GATIFLOXACIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; PLACEBO; PRAVASTATIN; SIMVASTATIN; THROMBOXANE A2; TIROFIBAN; TRIACYLGLYCEROL;

ACUTE DISEASE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; MORTALITY; RECURRENT DISEASE; SURVIVAL;

EID: 0036145794     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.1.25     Document Type: Article

References (34)

1. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations
2. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP)
3. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality
4. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
7. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
8. The effect of pravastatin on coronary evengs after myocardial infarction in patients with average cholesterol levels
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
10. Hyperlipidemia and coronary disease. Correction of the increasedbogenic potential with cholesterol reduction
11. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
12. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolemia
13. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia
14. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type lla hypercholesterolemia
15. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication
16. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
17. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques
18. Pravatatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
19. HMG-COA reductase inhibitors reduce MMP-9 secretion by macrophages
20. Effect of hydroxymethyl glutaryl coenzymes A reductase inhibitor therapy on high sensitive C-reactive protein
21. Beneficial effects of pravastatin (± cholestyramine/niacin) initiated immediately after a coronary events (The Randomized Lipid-Coronary Artery Disease [L-CAD] Study)
22. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial
23. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
24. Simvastatin reduces graft vessells disease and mortality after heart transplantation: A four-year randomized trial
25. Effect of pravastatin on outcomes after cardiac transplantation
26. HMG--CoA reductase inhibitors decreases CD 11b expression and CD 11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from pateints with hypercholesterolemia
27. Fluvastatin in acute myocardial infarction: Effects on early and late ischaemia events: The FLORIDA trial
28. Early statin treatment following acute myocardial infarction and 1-year survival
29. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study
30. Lipid-lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality
31. Early statin therapy s associated with markedly lower mortality in patients with acute coronary syndromes: Observation from OPUS-TIMI16
32. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction
33. The short-term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction
34. The A-to-Z trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein llb/llla inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy